Regulation - North America, Actavis

Filter

Current filters:

North AmericaActavis

Popular Filters

FDA investigating risk of stroke, heart attack and death with testosterone products

FDA investigating risk of stroke, heart attack and death with testosterone products

03-02-2014

The US Food and Drug Administration said on Friday that it is investigating the risk of stroke, heart…

AbbVieActavisAndrodermAndroGelAxironEli LillyMen's HealthNorth AmericaPharmaceuticalRegulationResearchTestosteroneUSA

Actavis confirms challenge to Allergan’s Restasis

22-01-2014

Generics drug major Actavis has confirmed that its Watson Laboratories unit has submitted an Abbreviated…

ActavisAllerganGenericsNorth AmericaOphthalmicsPatentsRegulationRestasisUSAWatson Pharmaceuticals

FTC approves final order regarding Actavis’ acquisition of Warner Chilcott

FTC approves final order regarding Actavis’ acquisition of Warner Chilcott

12-12-2013

Following a public comment period, the US Federal Trade Commission has approved a final order settling…

ActavisGenericsMergers & AcquisitionsNorth AmericaRegulationReproductiveWarner Chilcott

Actavis confirms challenge of Lilly’s Axiron patent

Actavis confirms challenge of Lilly’s Axiron patent

14-11-2013

US generics major Actavis confirms that it has filed an Abbreviated New Drug Application with the US…

ActavisAxironEli LillyGenericsLegalMen's HealthNorth AmericaPatentsRegulation

US FDA approval for Warner Chilcott's new oral contraceptive

26-07-2013

The US Food and Drug Administration have approved the use of a new oral contraceptive from Ireland-based…

ActavisLo Minastrin FeNorth AmericaPharmaceuticalRegulationReproductiveWarner Chilcott

Actavis confirms Vimpat patent challenge and gets OK for generic Opana

15-07-2013

US generics major Actavis (NYSE: ACT) confirmed on Friday (July 12) that it has filed an Abbreviated…

ActavisEndo Health SolutionsGenericsLegalNeurologicalNorth AmericaOpana ERPatentsRegulationUCBVimpat

Actavis wins generic Pulmicort Respules case; challenges AbbVie patent

02-04-2013

US generic drugs maker Actavis (NYSE: ACT) has confirmed that the US District Court for the District…

AbbVieActavisAndroGelAstraZenecaGenericsMarkets & MarketingMen's HealthNorth AmericaPatentsPulmicort RespulesRegulationRespiratory and Pulmonary

Actavis confirms patent challenge to Endo's Fortesta

04-03-2013

Generics drug giant Actavis (NYSE: ACT, formerly trading as Watson) has confirmed filing an Abbreviated…

ActavisEndo PharmaceuticalsFortestaGenericsMen's HealthNorth AmericaPatentsRegulation

Actavis settles with Mallinckrodt over Exalgo 32mg; Teva gains FDA OK for Adderall XR

14-02-2013

US generics drug major Actavis (NYSE: ACT) has reached a settlement with Mallinckrodt (NYSE: MKG) on…

ActavisAdderall XRExalgoGenericsMallinckrodtNeurologicalNorth AmericaPatentsRegulationShireTeva Pharmaceutical Industries

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

US FDA approves generics for Actavis and Lupin

06-07-2012

Switzerland-based generic drugmaker Actavis Group, now owned by US firm Watson Pharmaceuticals (NYSE:…

ActavisGenericsIntunivLupinLyricaNeurologicalNorth AmericaPfizerRegulationShireWatson Pharmaceuticals

FDA delays approval of QRxPharma's pain drug MoxDuo

29-06-2012

The US Food and Drug Administration has issued a Complete Response Letter (CRL) regarding the New Drug…

ActavisMoxDuoNeurologicalNorth AmericaPharmaceuticalQRxPharmaRegulationWatson Pharmaceuticals

Shire to face generic competition for Adderall XR from Actavis

25-06-2012

Shares in UK drugmaker Shire (LSE: SHP) fell around 9% to £17.82 in early trading this morning,…

ActavisAdderall XRGenericsNeurologicalNorth AmericaPharmaceuticalRegulationShireWatson Pharmaceuticals

Back to top